NeuShen Therapeutics raised more than $80 million in a Series B to advance three clinical-stage brain-health programs, spanning development from neurology to cognitive and neurological functional endpoints. The company is led by a transpacific leadership team spanning Shanghai and Boston. The financing highlights investor focus on late-stage brain-health assets as companies compete for programs positioned near clinical decision points. The disclosed proceeds are earmarked for advancing development across the trio of clinical-stage drugs.